Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Aug 2;113(4):355-7.
doi: 10.1161/CIRCRESAHA.113.302000.

Can we do better than dobutamine?

Elizabeth M McNally  1
Affiliations

Can we do better than dobutamine?

Elizabeth M McNally. Circ Res. .

Abstract

The development of dobutamine, an infusible inotropic drug for heart failure, was first described in 1975. Although this sympathomimetic was designed to increase cardiac output, it is far from ideal as a longterm safe strategy. New drugs for acute heart failure are needed, and to develop new approaches will require diverse expertise and resources.

PubMed Disclaimer

Conflict of interest statement

Disclosure: The author has not conflicts of interest relevant to this work.

Figures

Figure 1
Figure 1
The structures and effects of isoproterenol and dobutamine.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Tuttle RR, Mills J. Dobutamine: development of a new catecholamine to selectively increase cardiac contractility. Circulation research. 1975;36:185–196. - PubMed
    1. Overgaard CB, Dzavik V. Inotropes and vasopressors: review of physiology and clinical use in cardiovascular disease. Circulation. 2008;118:1047–1056. - PubMed
    1. Felker GM, O'Connor CM. Inotropic therapy for heart failure: an evidence-based approach. Am Heart J. 2001;142:393–401. - PubMed
    1. Ahlquist RP. Adrenergic receptors: a personal and practical view. Perspectives in biology and medicine. 1973;17:119–122. - PubMed
    1. Lefkowitz RJ, Mukherjee C, Coverstone M, Caron MG. Stereospecific (3H)(minus)-alprenolol binding sites, beta-adrenergic receptors and adenylate cyclase. Biochemical and biophysical research communications. 1974;60:703–709. - PubMed

Publication types

MeSH terms